Licensing opportunity: LMP1187 – a first-in-class CXCR4 antagonist for IPF and kidney fibrosis

LMP1187

LMC5000528 is an Australian clinical stage drug development company. Using its proprietary single domain antibody-like technology platform, LMC5000528 aims to solve challenging drug-targeting problems and generate a promising new class of single domain antibody-like protein therapeutics with the potential to treat some of today’s most challenging medical conditions, including fibrosis and solid tumors.

Licensing opportunity: LMP1566 x-sdAb platform to generate dual and bi-specific CAR therapies for solid tumors

LMP566

LMC5000528 is an Australian clinical stage drug development company. Using its proprietary single domain antibody-like technology platform, LMC5000528 aims to solve challenging drug-targeting problems and generate a promising new class of single domain antibody-like protein therapeutics with the potential to treat some of today’s most challenging medical conditions, including fibrosis and solid tumors.

Licensing Opportunity: LMP1857- A First-in-Class Mast Cell Modulator for Respiratory Infections Including Coronaviruses

LMP1857

LMC5001421 has developed a practical, scientific solution for upper respiratory infections, affecting billions of people per year.Respiratory infections, especially community acquired infections (ex:common cold, influenza and coronaviruses) all begin with flu-like symptoms (headache, sore throat, runny nose, muscle aches). And all respiratory infections exist with lung and total body inflammation, that if treated early, can prevent the progression to irreversible organ damage

Licensing opportunity: LMP1347 – the best nail penetrating topical onychomycosis therapy

LMP1347 （phase II/III clinical trial）

LMC5000628 is a European biotechnology company developing anti-bacterial, anti-fungal and anti-viral synthetic compounds based on their proprietary technology platform. Their lead compound LMP1347 is addressing the main limitations of current used topical onychomycosis treatments and has completed a phase II/III clinical trial in onychomycosis.

Licensing opportunity: LMP1309 - a GI-restricted JAK inhibitor for safe local treatment of IBD

LMP1309 （Phase II）

LMC5000554 is a European biotech startup developing small molecule drugs with innovative scaffolds (NCEs) that modulate clinically validated therapeutic targets in oncology and inflammatory/autoimmune diseases. Their lead gut restricted compound LMP1309 is addressing the main safety limitations of currently approved JAK inhibitors and is currently in phase 2 clinical trials for ulcerative systemic colitis.

LMP1154 licensing opportunity for China

LMP1154 （Preclinical stage）

LMC5000518' business is focused on the discovery and devel-opment of commercially and clinically important natural product antibiotics. The company's lead compound LMP1154 is a potent candidate drug for the treatment of systemic fungal infections, in particular infections by Candida spp. and other yeasts.

Immune Therapy Innovation: Alternative for Immune Disorders Treatments

LMP1150 & LMP1156（Phase I）

T1D is an autoimmune disease where the insulin-producing beta-cells in the pancreas are wrongly detected as foreign and destroyed by the immune system. Thereby, these cells stop producing insulin, the hormone that controls blood-sugar levels. There is no cure; once initiated, the disease will progress to complete destruction of the insulin-producing beta-cells.

LMP1156 is a peptide which interrupts the autoimmune process to stop the destruction of insulin-producing beta-cells and restores the ability of the remaining beta cells in the pancreas to naturally produce insulin.

Promising results from phase 1b study in patients with early type 1 diabetes

• LMP1156 has an excellent safety profile with no safety issues at any dose and no indication of disease exacerbation
• For the first time in humans, CD4+ T cells with cytolytic signature were detected in LMP1156-treated patients in line with the anticipated Mode of Action
• Artificial intelligence data mining analysis identified certain subgroups of patients (HLA DR4+) with apparent improved clinical and immunological responses
• Correlations between immune responses (treatment specific cCD4 cells) and clinical improvements were observed

Innovation - digestive disease area (GI) breakthrough

LMP1227 & LMP1228 （Phase III）

LMP1228 is a 5HT4 receptor agonist and a partial antagonist to 5HT3 receptors which is thought a promising therapeutic agent for IBS-C patients due to its accelerating effect on the gastrointestinal mobility.

LMP1227 is an antisense oligonucleotide therapeutic that targets mRNA for the production of human ICAM-1 and inhibits leukocyte migration to reduce inflammation. Safe and well tolerated compound with no drug related SAEs in more than 1,000 patients. Current development is focused on LMP1227 topical non-systemic enema application in ulcerative colitis, which in phase 2 clinical trials has shown a 50% improvement in Disease Activity Index with 6-months response from a single 6-week treatment course in moderate-to-severe ulcerative colitis. LMP1227 enema delivery is phase 3 clinical trial ready, with protocol design discussions for moderate-to-severe ulcerative colitis. Line extensions into oral administration planned. Next to ulcerative colitis potential application in Crohn's disease.

LMP1135 licensing opportunity for China

LMP1135（Phase I）

• Semisynthetic vascular-targeting heparin proteoglycan mimetic
• Conjugate of heparin and albumin
• Dual antiplatelet and anticoagulant activity

• Targets vascular injury site with a prolonged action in situ
• VWF-, collagen- and thrombininduced antiplatelet activity
• Reduces ischemia-reperfusion injury in kidneys (AKI)
• Bleeding time shorter than w UFH
• Antiproliferative effect on VSMCs
• Reduces tissue factor expression
• Inhibits the complement system
• Prevents / treats HIT
• Anticoagulant

• Hemodialysis vascular access failure (maturation, maintenance and revascularization)
• Critical limb ischemia
• Acute kidney injury
• ARDS/multi-organ failure (COVID-19 or other causes)
• HIT
• Thrombotic microangiopathies and alike syndromes
• All vascular surgeries
• Central venous catheter thrombosis in cancer patients

New Formulation Breakthrough: Oral Methotrexate for children

LMP1240 （On market）

• Methotrexate 2 mg/ml oral solution
• Bioequivalent to tablets, with a similar safety profile and appropriate excipients for both paediatrics and adults. Alcohol and sugar free
• Eliminates the need for crushing or splitting tablets, compounding tablets into a liquid formulation or administration by injection
• Ideal for paediatric patients requiring body surface area (BSA) dosing or those who have difficulty swallowing tablets, who don’t like the bitter taste of tablets or who are afraid of needles
• Palatable taste (orange flavour) and oral liquid form address risk of patient compliance to prescription
• Easy administration and accurate dosing with oral dosing syringe
• Stable at room temperature (below 25oC – ideal for shipment and storage). Can also be stored in refrigerator (2-8oC)
• Approved and launched in Europe: Centralized marketing authorization status across Europe, granted by European Medicines Agency (EMA) in March 2017. Successfully launched in UK market in December 2017 with uptake in major paediatric hospitals

H. pylori diagnostic test kit licensing opportunity for China

LMP1122（On market）

Private venture-backed LMC5000491 develops H. pylori related-products. Their proprietary pipeline contains amongst others LMP1122, a novel Helicobacter blood test which both detects the presence of H. pylori and discriminates between pathogenic and non-pathogenic strains of H. pylori. LMP1122 is available for licensing & manufacturing in China. LMC5000491 is also open to selling the program with global rights. Lingmed is the exclusive BD agent in China.